PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28337636-4 2017 Zymosan-induced DNA-binding activity of nuclear factor-kappa B (NF-kappaB) was attenuated by EVO, which was achieved through inhibitory effects on the phosphorylation of inhibitory kappaB alpha and p65 nuclear translocation, but there was very little association with mitogen-activated protein kinase activation. evodiamine 93-96 RELA proto-oncogene, NF-kB subunit Homo sapiens 198-201 30789361-10 2019 These findings provide evidences that EVO suppresses the migration and invasion of CRC cells by inhibiting the acetyl-NF-kappaB p65 by Sirt1, resulting in suppression of metalloproteinase-9 expression in vitro and in vivo. evodiamine 38-41 RELA proto-oncogene, NF-kB subunit Homo sapiens 128-131 31894007-9 2019 Compared with LPS group, the pre-treatment of evodiamine obviously improved the cell survival rate, promoted the secretion of NO, inhibited the expression of TLR4 and NF-kappaBp65 and down-regulated the mRNA expression of NF-kappaBp65. evodiamine 46-56 RELA proto-oncogene, NF-kB subunit Homo sapiens 167-179 31894007-9 2019 Compared with LPS group, the pre-treatment of evodiamine obviously improved the cell survival rate, promoted the secretion of NO, inhibited the expression of TLR4 and NF-kappaBp65 and down-regulated the mRNA expression of NF-kappaBp65. evodiamine 46-56 RELA proto-oncogene, NF-kB subunit Homo sapiens 222-234 30789361-7 2019 In EVO-induced cells, the intracellular NAD+/NADH ratio was increased, the level of Sirt1 was increased, and acetyl-NF-kappaB P65 was decreased. evodiamine 3-6 RELA proto-oncogene, NF-kB subunit Homo sapiens 116-129 30643424-9 2019 In vivo, combination treatment of the xenograft model with EVO and GEM led to a significant reduction in tumor volume growth and inhibited the activation of NF-kappaB p65 with no obvious adverse reactions. evodiamine 59-62 RELA proto-oncogene, NF-kB subunit Homo sapiens 167-170 30320369-7 2018 The results revealed that Evo dose-dependently reduced the protein and mRNA expression levels of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and IL-1beta, and inhibited the levels of phosphorylated (p-) inhibitor of NF-kappaBalpha, p-extracellular signal-regulated kinase, p-c-Jun N-terminal kinase and p-p38, and decreased the nuclear translocation of NF-kappaB/p65 in BEAS-2B cells infected with MSSA. evodiamine 26-29 RELA proto-oncogene, NF-kB subunit Homo sapiens 373-376 26546460-9 2015 Further investigation revealed that evodiamine inhibited the translocation of NF-kappaB p65, which involves the regulation of MMP-2 expression in cancer invasion. evodiamine 36-46 RELA proto-oncogene, NF-kB subunit Homo sapiens 78-91 26590365-0 2016 Evodiamine Suppresses ABCG2 Mediated Drug Resistance by Inhibiting p50/p65 NF-kappaB Pathway in Colorectal Cancer. evodiamine 0-10 RELA proto-oncogene, NF-kB subunit Homo sapiens 71-74 26590365-5 2016 Interestingly, phosphorylation of NF-kappaB pathway, particularly p50/p65, was also inhibited by Evo treatment. evodiamine 97-100 RELA proto-oncogene, NF-kB subunit Homo sapiens 70-73